Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NBRI. Pink Current Company.
https://www.otcmarkets.com/stock/NBRI/quote
$DSGT. Rumble Motors Video
https://www.startengine.com/rumblemotors
Unbelievable Low Authorized Shares.
https://www.otcmarkets.com/stock/LEAS/security
$RLFTF. Coronavirus Technology Watch
https://moneymidnight.com/2020/10/relief-therapeutics-otcrlftf-enters-into-coronavirus-technology-watch-program/
$RLFTF. 23.09.2020 - 08:30 COMPANY / HEALTH
Relief partner requests admission for corona medication
NeuroRx seeks emergency clearance for RLF-100. It should be used in corona patients in critical condition.
The application is based on a case-control study, in which patients' disease progression is compared
The application is based on a case-control study in which the disease processes of patients treated with either RLF-100 or standard therapy were compared. (Image: Gaetan Bally / Keystone)
(AWP) The research partner of the Geneva biotech company Relief Therapeutics ( RLF 0.578 10.31% ) , NeuroRx, has submitted an authorization application for the drug RLF-100 (Aviptadil) in the USA. RLF-100 is to be used as an emergency medication in corona patients in critical condition.
NeuroRx filed a permit application with the US Food and Drug Administration (FDA), which announced relief on Wednesday. With RLF-100, Corona patients are to be treated in intensive care units, for which all permitted treatment methods are exhausted.
The application is based on a case-control study in which the disease processes of patients treated with either RLF-100 or standard therapy were compared. The treatment with RLF-100 showed a three-fold better result in terms of survival, recovery from respiratory failure and other parameters.
However, the treatment also has its drawbacks: Thus, in the tests in two patients treated with Aviptadil, a hypotension - ie low blood pressure - was observed. However, these have been successfully treated with vasopressors. Diarrhea was observed in four of the 21 patients treated with Aviptadil and in three of the 30 control patients.
The permit for the use of RLF-100 as an emergency medicine addresses the same patient population that will be treated in the framework of the "Expanded Access" protocol approved by the FDA, the communication continues. Many patients who may have benefited from this "expanded access" did not receive access to clinical trials, said NeuroRx chief Jonathan Javitt, according to the announcement. All too often, these are patients with lower socioeconomic status.
$HNCKF/TSLA Partnership Confirmed?
(
$HNCKF. Barchart 100% Buy
https://www.barchart.com/stocks/quotes/HNCKF/opinion
$ATDS. Same CEO That’s Doing ALL THIS.
https://ih.advfn.com/p.php?pid=nmona&article=83185186
$GRST. Same here in with 4m this morning 17/18.
Once the i and t’s get finished dotted and crossed, I see this running 1000% from here.
$RLFTF. RLF-100, Aviptadil, VIP Info
$RLFTF. Overheard Around the Web
Here’s what one trader on StockTwits recently had to say in regards to PFE:
$GSK $PFE $AMGN $BIIB
BIG GAINS TRADE IDEA for important CV Therapeutic:
Lots of RLF-100 testing happening in India with major excitement by Doctors and health institutions due to the rapid recovery from the SARS element (e.g. respiratory failure) of Covid-19, thanks to RLF-100's ability to STOP the REPLICATION of the virus within the lung cells (targeting ACE2 receptors). [1]
RLF-100 is a EU and US patented peptide formulation in both IV and Inhalable forms, already approved by the FDA for clinical trials [2] and emergency use [3]. The patent is owned by the Swiss-based Relief Therapeutics [4] (SIX exchange: $RLF / US OTC exchange: $RLFTF) in coordination with U.S. partner company, NeuroRX, headed by major Pharma / FDA / Presidential affiliate, Jonathon Javitt [5]
Pers. PT: $3.50 – $5.50 by OCT / NOV, potential for $8-$10+ by Q1 imo
[1] https://newsrediff.com/covid-19-treatment-rlf-100-or-aviptadil-is-explored-for-treating-viral-infection-here-is-why/
https://www.cfdtrading.com/pfizer-inc-pfe-down-0-29-breaks-below-20-day-average-pin-bar-pattern-appearing-on-chart/166752/
$RLFTF. Compassionate Care Protocol to be Conducted at Rambam Healthcare Campus in Coordination with the Government of Israel
https://infomeddnews.com/relief-therapeutics-holding-sa-announces-plans-to-test-aviptadil-for-treatment-of-covid-induced-acute-respiratory-distress-syndrome/
$RLFTF. ( yayabar ) Posted on Yahoo finance
$RLFTF. Take a look at this.
yayabar31 minutes ago
This. Is. It.
This was the original study of RLF 100 in the setting of ARDS and sepsis performed in 1999 but was not published.
https://assets.researchsquare.com/files/rs-52237/v1/ebab9c23-ca28-4c27-b367-2947a1c244ee.pdf
COVID 19 infection and its effect causing illness/death is due to “Cytokine storm” which in mild to moderate cases causes hospitalization and in severe case leads to ICU level of care due to ARDS and eventually leads to death.
This trial data was a reason enough for FDA to approve phase 2/3 trial for RLF 100.
If the data from Dr Youssef from Houston Methodist this week shows similar response as noted earlier this month, then the therapeutic effect of RLF 100 will not be accounted by any placebo effect.
Game changer for stock price: Trial for RLF 100 now includes the majority of hospitalized COVID 19 patients. It will replace Remdesevir as a drug of choice which is now given to every hospitalized patients with low oxygen saturation (lowest threshold to start the medication)
Inhalation RLF: Relief is the one with inhalation approved formulary of VIP. It will take minimum 2 years even for big pharmas to go through the process of preliminary approval to start human trial. If IV infusion of RLF 100 works, inhaled RLF 100 can be used concurrently in hospitalized patients to increase therapeutic effect and decrease side effects. Use in the outpatient settings/milder cases all over the world will be in hundreds of millions.
FDA approval: Mid October
Will only happen after the randomized trial result is out. Enrollments should be done by the 15th of September per Dr Javits’s interview with Dr Yo. Trial will run for 2 weeks after last enrollment. Data processing and review will take another 2 weeks. By mid-October FDA will have the data and decision will be made.
The world can then take a deep breath of Relief.
$RLFTF. Complete article
A Swiss biotech company has obtained US approval for a Corona vehicle. Patients therefore respond well to Aviptadil, which has been developed to treat potency problems. Relief Therapeutics is now also expecting the biggest financial breakthrough.
Daniel Kestenholz
Kommentare
RELIEFTHERAPEUTICS.COM
The Swiss biotech company Relief Therapeutics hopes with Aviptadil for the big breakthrough.
1/4
The Swiss biotech company Relief Therapeutics hopes with Aviptadil for the big breakthrough.
The drug developed for potency problems therefore also shows clear advantages in the treatment of Covid patients.
2/4
The drug developed for potency problems therefore also shows clear advantages in the treatment of Covid patients.
AFP
The US Food and Drug Administration (FDA) has given Aviptadil the green light for an accelerated authorization procedure.
3/4
The US Food and Drug Administration (FDA) has given Aviptadil the green light for an accelerated authorization procedure.
RELIEFTHERAPEUTICS.COM
The Swiss Raghuram Selvaraju, Chairman of the Board of Relief Therapeutics, is convinced of the success of the Corona Medium.
4/4
The Swiss Raghuram Selvaraju, Chairman of the Board of Relief Therapeutics, is convinced of the success of the Corona Medium.
The corona pandemic is also giving new wings to the Swiss pharmaceutical industry. Lonza is producing a vaccine developed by the US group Moderna at the Welsh plant at Visp. The biotech company Relief Therapeutics, which is listed on the Swiss stock exchange, also shows great progress with a Corona device.
Relief Therapeutics, headquartered in Geneva, holds valid patents in the United States and Europe for the drug RLF-100 (Aviptadil) - a drug developed for erectile dysfunction. Aviptadil also has the potential to treat critically ill Covid-19 patients. It shows a quick recovery in case of respiratory failure.
ADVERTISING
Ads by Teads
Aviptadil is an innovative drug for inhalation in moderately and severely ill corona patients. This remedy may prevent patients from having to be connected to breathing apparatus - or they may no longer be relied on breathing machines within a few days.
Promotes blood oxygen
In early August, Aviptadil in the United States received the accelerated extended clearance procedure for respiratory failure by Covid-19. The remedy was actually developed to treat erectile dysfunction. Aviptadil is combined with another ingredient called Phentolamine to treat erectile dysfunction. When both drugs are taken together, they promote blood flow in and out of the penis, which keeps it firm. However, as tests show, Aviptadil should also treat Covid-19 patients with lung disease. X-rays thus indicate a rapid improvement in blood oxygen and that the lungs are pumping oxygen through the body again.
RLF-100 is considered to be the first drug to block the proliferation of coronavirus in human lung cells and monocytes. The hope is that by inhaling the drug in a wide range of patients with corona-causing respiratory problems, the remedy will prove to be beneficial. Clinical trials begin in September.
A first test phase will include patients in hospitals. With successful use, trials are being extended to patients at home who are only mildly or moderately ill with the virus, as Relief Therapeutics and its US partner company Neurorx announced this week.
"Hundreds of millions of dollars" revenue expected
The share value of Relief Therapeutics exploded in early August from a unit price of around 0.03 francs per share to 0.70 francs, with the price stabilizing at around 0.45 francs. The price increase followed the approval of the US Drug Administration (FDA) of Aviptadil tests.
After difficult years of operation, Board of Directors Chairman Raghuram Selvaraju (42) justifies the current stock market valuation of more than one billion francs. In an interview with the business portal "The Market", he estimates the probability of a permit at 60 to 70 percent.
The active ingredient has been used for many years for various indications. The company is confident in terms of its security. "Our active ingredient," said the Swiss, "could bring in hundreds of millions of dollars a year."
The drug developed for potency problems therefore also shows clear advantages in the treatment of Covid patients.
2/4
The drug developed for potency problems therefore also shows clear advantages in the treatment of Covid patients.
AFP
The US Food and Drug Administration (FDA) has given Aviptadil the green light for an accelerated authorization procedure.
3/4
The US Food and Drug Administration (FDA) has given Aviptadil the green light for an accelerated authorization procedure.
RELIEFTHERAPEUTICS.COM
The Swiss Raghuram Selvaraju, Chairman of the Board of Relief Therapeutics, is convinced of the success of the Corona Medium.
4/4
The Swiss Raghuram Selvaraju, Chairman of the Board of Relief Therapeutics, is convinced of the success of the Corona Medium.
The corona pandemic is also giving new wings to the Swiss pharmaceutical industry. Lonza is producing a vaccine developed by the US group Moderna at the Welsh plant at Visp. The biotech company Relief Therapeutics, which is listed on the Swiss stock exchange, also shows great progress with a Corona device.
Relief Therapeutics, headquartered in Geneva, holds valid patents in the United States and Europe for the drug RLF-100 (Aviptadil) - a drug developed for erectile dysfunction. Aviptadil also has the potential to treat critically ill Covid-19 patients. It shows a quick recovery in case of respiratory failure.
Aviptadil is an innovative drug for inhalation in moderately and severely ill corona patients. This remedy may prevent patients from having to be connected to breathing apparatus - or they may no longer be relied on breathing machines within a few days.
Promotes blood oxygen
In early August, Aviptadil in the United States received the accelerated extended clearance procedure for respiratory failure by Covid-19. The remedy was actually developed to treat erectile dysfunction. Aviptadil is combined with another ingredient called Phentolamine to treat erectile dysfunction. When both drugs are taken together, they promote blood flow in and out of the penis, which keeps it firm. However, as tests show, Aviptadil should also treat Covid-19 patients with lung disease. X-rays thus indicate a rapid improvement in blood oxygen and that the lungs are pumping oxygen through the body again.
RLF-100 is considered to be the first drug to block the proliferation of coronavirus in human lung cells and monocytes. The hope is that by inhaling the drug in a wide range of patients with corona-causing respiratory problems, the remedy will prove to be beneficial. Clinical trials begin in September.
A first test phase will include patients in hospitals. With successful use, trials are being extended to patients at home who are only mildly or moderately ill with the virus, as Relief Therapeutics and its US partner company Neurorx announced this week.
"Hundreds of millions of dollars" revenue expected
The share value of Relief Therapeutics exploded in early August from a unit price of around 0.03 francs per share to 0.70 francs, with the price stabilizing at around 0.45 francs. The price increase followed the approval of the US Drug Administration (FDA) of Aviptadil tests.
After difficult years of operation, Board of Directors Chairman Raghuram Selvaraju (42) justifies the current stock market valuation of more than one billion francs. In an interview with the business portal "The Market", he estimates the probability of a permit at 60 to 70 percent.
The active ingredient has been used for many years for various indications. The company is confident in terms of its security. "Our active ingredient," said the Swiss, "could bring in hundreds of millions of dollars a year.
$RLFTF. Hey there 3BB. Right There With You. Got In Super Early, Still Holding All Shares Tight.
Got Sales Sitting At 9.50 / 12.50. And My Last 100G Sitting At 19.50
$RLFTF. Great Job J-Belfort
$RLFTF. About to announce a new COVID-19 distributor ?
Imagine if it’s McKesson.
$RLFTF. tovc4me. Outstanding Job
Holding All Shares Tight.
RLFTF Long.
$RLFTF Found this from one of the comments of the article.
StopWhiningAlready
Comments (6)
Today, 11:43 AM
I started looking at RLFTF yesterday after my wife, an ICU nurse, texted me that they were using a new drug on patients that she had not heard of, nor heard of the company behind it. Doing some background, I found they had a compelling story and a novel way of approaching treatment. We'll know in a few days how patients on the unit are responding as they are part of the emergency use cohort. Results are hard to argue with, though the number of test cases is still small compared to other treatment protocols.
Like the author, i was equally impressed with the team leading their partner organization, NeuroRx. The two together are a compelling combination and a team i wouldn't want to bet against. They don't seem to know how not to succeed. There's also a lot of promise in their other drug, NRX-101, which is used for the treatment of suicidal depression. What a nice 1-2 punch this could be, no?
I was surprised to see this morning that RLFTF was down considerably at the open for no reason that I could find. I assume the Russian's announcement took the wind from everyone's sales. Given the low share price and the upside potential, i picked some up to hang onto for the next 24-36 months.
Wow because mistake ever
$RLFTF. the British media's Daily Mail Internet version reported that 16 patients with severe Corona19 who had been administered abiftadil in the United States had improved after removing their respirators in four days. Relief Therapeutics revealed that blood oxygen saturation was restored on chest X-ray images of patients who recovered after receiving abitadil.
Accordingly, there is a possibility that Avitadiil will emerge as a new treatment for severely ill patients with Corona 19 following remdesivir.
$RLFTF. Korean ?
Used Google translate ( Korean )
http://m.dongascience.donga.com/news.php?idx=38943
'Abiftadil (RLF-100)' jointly developed by Neurorex, a joint pharmaceutical company in the US and Israel, and Relief Therapeutics, a Swiss bio company, as a treatment for erectile dysfunction, treats severe patients with novel coronavirus infections (COVID-19, Corona 19). It is known to be effective in attracting attention.
On the 8th (local time), the British media's Daily Mail Internet version reported that 16 patients with severe Corona19 who had been administered abiftadil in the United States had improved after removing their respirators in four days. Relief Therapeutics revealed that blood oxygen saturation was restored on chest X-ray images of patients who recovered after receiving abitadil.
Accordingly, there is a possibility that Avitadiil will emerge as a new treatment for severely ill patients with Corona 19 following remdesivir.
RLF-100 is a drug made by conjugating phentolamine to a patented synthetic substance called "vascular acting intestinal polypeptide (VIP)." Currently, in Europe, it is sold under the product name'Invikov' as a treatment for erectile dysfunction.
70% of VIPs in the body are concentrated in the lungs. They are known to act by binding to type 2 alveolar cells and inhibiting the cytokine, a protein that causes inflammation.
RLF-100 has also proven its effectiveness in alleviating lung infections in previous animal experiments. Recently, a clinical trial in 76 patients has been shown to relieve bronchospasm, relieve pulmonary arterial hypertension, and treat pulmonary inflammation, including decreased inflammatory cytokine protein.
Relief Therapeutics said, "It is believed that RLF-100 has the potential to provide effective treatment for patients with acute respiratory distress syndrome among patients with COVID-19."
RLF-100 was designated as an orphan drug to treat acute respiratory distress syndrome by the US FDA in 2001, and was also approved as a treatment for pulmonary arterial hypertension in 2005.
In June, the U.S. Food and Drug Administration (FDA) designated a procedure for rapid use as a treatment for respiratory failure in patients with severe COVID-19. Currently, a phase 2 clinical trial on 70 corona19 patients is in progress.
#Abiptadil#RLF-100#Relief Therapeutics#Coronavirus#Corona19#Severe patient treatment
Related articles
Research on anticancer properties in pepper to find new anticancer target candidates
The rainy season comes to typhoons... The 5th typhoon'Rose' North Korea 10th Influence Zone
40,000~90,000 won per dose of Corona 19 vaccine?... Bill Gates supplies it for just 3,500 won.
They chose fins instead of hands... but nature chose an aquatic animal with finger bones
"The coronavirus will not disappear. It is unlikely to make an effective vaccine
$RLFTF. RLF-100. Just Out.
https://www.medpagetoday.com/infectiousdisease/covid19/87990
$RLFTF. NDTV. INDIA. 45K Views.
$RLFTF. RLF-100. Details.
In late March
Preparing for a phase II trial of intravenous Aviptadil for COVID-19-associated acute respiratory distress; filed an IND with the FDA.
April 9, it entered FDA clinical trials at Thomas Jefferson University Hospital in Philadelphia to treat acute respiratory distress syndrome in COVID-19; the trial will enroll patients who are already on mechanical ventilation;
May 11, Neurorx filed investigational protocol with FDA under the Coronavirus Treatment Acceleration Program for a phase II/III study assessing inhaled drug in patients with non-acute lung injury due to COVID-19;
May 14, final manufacturing completed for phase IIb/III trial to assess intravenous formulation in individuals on mechanical ventilation; enrollment initiated at first U.S. site;
June 2, treated first of 120 patients in phase IIb/III study; primary endpoints are mortality and index of respiratory distress;
June 8, expanded a phase II study to include patients receiving high flow oxygen and noninvasive ventilation, in addition to those on ventilators;
June 11, added Houston Methodist Hospital as a research site;
June 24, FDA granted fast track designation for treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19;
July 16, data monitoring committee reviewed findings from the first 30 patients, concluding that the study should continue;
July 29, FDA granted expanded access protocol to those ineligible for enrollment in clinical trial, including pregnant women, who exhausted approved therapies;
Aug. 3, Neurorx and Relief said RLF-100 allowed rapid recovery from respiratory failure in the most critically ill COVID-19 patients; independent researchers reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes; RLF-100 was granted fast track designation by the FDA and is being developed as a material threat medical countermeasure with the U.S. NIH and other federal agencies; RLF-100 is a patented formulation of vasoactive intestinal polypeptide;
Aug. 6, FDA approved the IND for the phase II/III study
Details From Bioworld.com. (Therapeutics In Development)
$RLFTF. Details, Aviptadil (RLF-100,Inhaled)
Phase II/III Aviptadil (RLF-100, inhaled) Neurorx Inc.; Relief Therapeutics Holding SA Preparing for a phase II trial of intravenous Aviptadil for COVID-19-associated acute respiratory distress; filed an IND with the FDA in late March for a phase II trial; as of April 9, it entered FDA clinical trials at Thomas Jefferson University Hospital in Philadelphia to treat acute respiratory distress syndrome in COVID-19; the trial will enroll patients who are already on mechanical ventilation; as of May 11, Neurorx filed investigational protocol with FDA under the Coronavirus Treatment Acceleration Program for a phase II/III study assessing inhaled drug in patients with non-acute lung injury due to COVID-19; as of May 14, final manufacturing completed for phase IIb/III trial to assess intravenous formulation in individuals on mechanical ventilation; enrollment initiated at first U.S. site; as of June 2, treated first of 120 patients in phase IIb/III study; primary endpoints are mortality and index of respiratory distress; as of June 8, expanded a phase II study to include patients receiving high flow oxygen and noninvasive ventilation, in addition to those on ventilators; as of June 11, added Houston Methodist Hospital as a research site; as of June 24, FDA granted fast track designation for treatment of acute lung injury/acute respiratory distress syndrome associated with COVID-19; as of July 16, data monitoring committee reviewed findings from the first 30 patients, concluding that the study should continue; as of July 29, FDA granted expanded access protocol to those ineligible for enrollment in clinical trial, including pregnant women, who exhausted approved therapies; as of Aug. 3, Neurorx and Relief said RLF-100 allowed rapid recovery from respiratory failure in the most critically ill COVID-19 patients; independent researchers reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes; RLF-100 was granted fast track designation by the FDA and is being developed as a material threat medical countermeasure with the U.S. NIH and other federal agencies; RLF-100 is a patented formulation of vasoactive intestinal polypeptide; as of Aug. 6, FDA approved the IND for the phase II/III study
8/6/20
$RLFTF - FDA has made a potentially lifesaving drug immediately available.
“By granting this Expanded Access protocol, FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment,” said Dr. Jonathan C. Javitt, MD, MPH, NeuroRx’s CEO. “We thank the FDA’s pulmonary division for its rapid and proactive implementation of the Coronavirus Treatment Acceleration Program, and we aspire to demonstrate broad safety and efficacy for RLF-100 in our ongoing clinical trial.”
$RLFTF - Known to break NEWS Sunday nights.
For all you who are still on the fence.
It’s Time To Get In.
Good Morning ThreeBB. We Riding Long Right.
$RLFTF. That’s what they said at .04 , .30 , .20. .40 And now .84.
$RLFTF. Well Played
$RLFTF. Let The Party Begin.
The trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the need for hospital admission.
This Is Money And Of Course Life-saving treatment.
https://money.yahoo.com/fda-grants-inhaled-ind-rlf-050000708.html
$RLFTF Damn my heart can’t stop beating.
I had said $10. In two months. You called it. Very much sooner.
$RLFTF I’ve been waiting for this one.
This is going to take us over the top.